Trial Profile
Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary)
- Indications T-cell leukaemia; T-cell lymphoma
- Focus Therapeutic Use
- 07 Jun 2011 Planned end date changed from 1 Jul 2009 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 07 Jun 2011 Planned end date changed from 1 Jul 2009 to 1 Jul 2012 as reported by ClinicalTrials.gov.
- 24 Feb 2011 Planned end date changed from 1 Mar 2009 to 1 Jul 2009 as reported by ClinicalTrials.gov.